| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.41B | 1.68B | 1.89B | 2.11B | 2.18B |
| Gross Profit | 832.95M | 1.00B | 1.09B | 1.20B | 1.32B |
| EBITDA | 57.30M | 89.22M | 95.34M | 135.28M | 253.93M |
| Net Income | -131.96M | -20.33M | -15.29M | 36.61M | 153.75M |
Balance Sheet | |||||
| Total Assets | 680.06M | 860.81M | 950.88M | 953.94M | 919.54M |
| Cash, Cash Equivalents and Short-Term Investments | 1.69M | 1.95M | 2.54M | 1.79M | 2.39M |
| Total Debt | 354.30M | 936.11M | 972.65M | 896.01M | 791.05M |
| Total Liabilities | 1.26B | 1.31B | 1.39B | 1.39B | 1.34B |
| Stockholders Equity | -578.48M | -451.59M | -441.93M | -438.18M | -424.95M |
Cash Flow | |||||
| Free Cash Flow | -17.69M | 3.64M | -66.08M | -33.32M | 233.11M |
| Operating Cash Flow | -3.28M | 27.14M | -9.03M | 36.14M | 300.01M |
| Investing Cash Flow | -17.69M | -26.29M | -58.35M | -70.61M | -66.64M |
| Financing Cash Flow | 20.71M | -1.44M | 68.13M | 33.87M | -235.22M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $568.47M | 12.45 | 9.20% | 7.86% | -4.26% | ― | |
65 Neutral | $1.35B | 18.08 | 8.12% | 2.39% | 1.78% | -25.36% | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
59 Neutral | $1.23B | 11.21 | -1.98% | 4.16% | 4.34% | -141.36% | |
57 Neutral | $1.39B | 6.47 | 26.15% | 1.84% | -6.03% | ― | |
48 Neutral | $75.68M | -2.12 | -9999.00% | ― | -9.47% | 48.11% | |
41 Neutral | $75.68M | 0.67 | 16.35% | ― | -16.95% | -88.00% |
On March 12, 2026, Sleep Number posted a detailed investor presentation outlining the progress of its ongoing turnaround and financial and operational transformation. The company highlighted 2025 net sales of $1.41 billion in line with guidance, adjusted EBITDA of $78 million above outlook, more than $185 million in annualized cost reductions with another $50 million being executed, and a reshaped leadership team focused on restoring profitable growth.
Management said 2025 was a pivotal year, citing the successful launch of its ComfortMode mattress, which exceeded sales expectations by 3.5 times, and the planned March 23 reset of its entire product line to emphasize comfort, durability, adjustability and value at more approachable premium price points. Sleep Number is also rebuilding its marketing engine, pursuing new physical and digital distribution, and working to address liquidity and capital structure, including retaining Guggenheim Securities to evaluate options to improve its balance sheet and financial flexibility as it targets topline growth in the second half of the year and a return to free cash flow generation in 2026.
The most recent analyst rating on (SNBR) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Sleep Number stock, see the SNBR Stock Forecast page.
On March 10, 2026, Sleep Number’s board appointed Kelly F. Baker as the company’s Controller and Principal Accounting Officer, effective March 11, 2026, formalizing a role she had held on an interim basis since July 21, 2025. The move solidifies the company’s finance leadership structure, drawing on Baker’s public accounting background and finance roles at Miromatrix Medical, Donaldson Company, The Tile Shop, and Virtual Radiologic, and comes with no special arrangements or related-party transactions disclosed in connection with her selection.
The most recent analyst rating on (SNBR) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on Sleep Number stock, see the SNBR Stock Forecast page.
On January 28, 2026, Sleep Number announced a three-year strategic partnership and investment deal with three-time Super Bowl champion Travis Kelce, who has used the company’s products since 2019. Under the agreement, Kelce and his company TMK Enterprises LLC will collaborate on national advertising and digital content to promote the performance and wellness benefits of Sleep Number beds, while Kelce receives cash and restricted stock units that vest over three years and commits to buying additional shares on the open market, making him one of the company’s largest shareholders with under 5% ownership. The deal deepens Sleep Number’s long-standing relationship with the NFL—where 83% of players have Sleep Number beds—and is a key element of the company’s broader effort to overhaul its marketing strategy, sharpen brand visibility and attract younger consumers by leveraging Kelce’s high profile and alignment with sleep-focused performance.
The most recent analyst rating on (SNBR) stock is a Hold with a $10.50 price target. To see the full list of analyst forecasts on Sleep Number stock, see the SNBR Stock Forecast page.